|
|
Volumn 509, Issue 7502, 2014, Pages
|
|
Nanotechnology: Deliver on a promise
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BRENTUXIMAB VEDOTIN;
CANCER ANTIBODY;
DOXORUBICIN;
MACROGOL;
NANOCARRIER;
TRASTUZUMAB EMTANSINE;
ANTIBODY;
CAMPTOTHECIN;
MONOCLONAL ANTIBODY;
NANOPARTICLE;
NUCLEAR MAGNETIC RESONANCE IMAGING AGENT;
RNA;
CANCER CHEMOTHERAPY;
DRUG EFFICACY;
HUMAN;
MOLECULARLY TARGETED THERAPY;
NANOTECHNOLOGY;
NONHUMAN;
NOTE;
PARTICLE SIZE;
PHASE 1 CLINICAL TRIAL (TOPIC);
PHASE 2 CLINICAL TRIAL (TOPIC);
PHASE 3 CLINICAL TRIAL (TOPIC);
PRIORITY JOURNAL;
TREATMENT OUTCOME;
ANTINEOPLASTIC ACTIVITY;
BIOMEDICAL ENGINEERING;
BREAST CANCER;
CANCER CELL;
CANCER PATIENT;
CANCER THERAPY;
CELL KILLING;
DRUG DELIVERY SYSTEM;
DRUG POTENCY;
DRUG SAFETY;
DRUG TARGETING;
KAPOSI SARCOMA;
LUNG CANCER;
LYMPHOMA;
NEOPLASM;
NUCLEAR MAGNETIC RESONANCE IMAGING;
OVARY CANCER;
PANCREAS CANCER;
RNA INTERFERENCE;
SHORT SURVEY;
ANTIBODIES, MONOCLONAL, HUMANIZED;
CAMPTOTHECIN;
CYCLODEXTRINS;
DOXORUBICIN;
DRUG DELIVERY SYSTEMS;
HUMANS;
IMMUNOCONJUGATES;
MAYTANSINE;
MOLECULAR TARGETED THERAPY;
NANOMEDICINE;
NANOPARTICLES;
POLYETHYLENE GLYCOLS;
CANCER;
DRUG;
NANOTECHNOLOGY;
|
|
EID: 84901610137
PISSN: 00280836
EISSN: 14764687
Source Type: Journal
DOI: 10.1038/509s58a Document Type: Note |
|
Times cited : (29)
|
|
References (3)
|
